Showing results (321-330 of 337) with videos related to

Sort By:
Pageof 34
The Lancet. HIV|February 9, 2026
Inpatient initiation of tuberculosis preventive therapy with 1 month of isoniazid and rifapentine for adults with advanced HIV disease and cryptococcal meningitis (IMPROVE): a non-inferiority, randomised controlled trialJayne Ellis, Gila Hale, Laura J Nsangi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 16, 2017
Advanced Human Immunodeficiency Virus Disease in Botswana Following Successful Antiretroviral Therapy Rollout: Incidence of and Temporal Trends in Cryptococcal MeningitisMark W Tenforde, Margaret Mokomane, Tshepo Leeme, et al.
Open Forum Infectious Diseases|October 22, 2024
Computed Tomography of the Head Before Lumbar Puncture in Adults With Suspected Meningitis in High-HIV Prevalence SettingsJames Milburn, Christopher G Williams, Kwana Lechiile, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 3, 2025
Recent Antiretroviral Therapy Initiation Is Associated With Increased Mortality Risk in HIV-associated Cryptococcal Meningitis: An Analysis of Clinical Trial Data From AfricaMelanie Moyo, David S Lawrence, James Jafali, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 29, 2021
Empirical audit and review and an assessment of evidentiary value in research on the psychological consequences of scarcityMichael O'Donnell, Amelia S Dev, Stephen Antonoplis, et al.
The Lancet. Global Health|April 27, 2025
Personalised risk-prediction tools for cryptococcal meningitis mortality to guide treatment stratification in sub-Saharan Africa: a prognostic modelling study based on pooled analysis of two randomised controlled trialsThomas H A Samuels, Sile F Molloy, David S Lawrence, et al.
Trials|March 25, 2026
Fluconazole plus flucytosine versus fluconazole alone for adults with HIV-associated cryptococcal antigenaemia identified through screening: a multi-centre phase III randomised-controlled trialKyla Murphy, Jeremy S Nel, Mahomed-Yunus Moosa, et al.
Trials|January 16, 2019
Correction to: AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority TrialDavid S Lawrence, Nabila Youssouf, Síle F Molloy, et al.
Trials|November 25, 2018
AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority TrialDavid S Lawrence, Nabila Youssouf, Síle F Molloy, et al.
Open Forum Infectious Diseases|December 1, 2025
Epstein-Barr Virus Central Nervous System Infections and Mortality Risk in Patients Presenting With Suspected Meningitis: Results From the Botswana National Meningitis Survey and the Harare Meningitis Aetiology StudyJayne Ellis, James Milburn, Kebatshabile Ngoni, et al.
Pageof 34